TurnerJR. Editor's commentary: a vision for the journal’s continued growth. Drug Information Journal. 2011:45(2);113–117.
2.
KrucoffM. Focus on the Cardiac Safety Research Consortium. Drug Information Journal. 2011:45(3);241–244.
3.
SmithBStocumMVerstCCohenO. Building value through biomarkers: the “Smarter Development” initiative [published online ahead of print April 12, 2012]. Drug Information Journal. doi: 10.1177/0092861512441392.
4.
SilbermanSBreitfeldPButzbachA. Imaging biomarkers in oncology drug development. Journal for Clinical Studies. 2012:4(3);22–24.
5.
TurnerJR. Editor's commentary: regulatory science and the science of safety. Drug Information Journal. 2011:45(3);221–227.
6.
TurnerJR. Editor’s commentary: assessing worst-case scenarios in regulatory science. Drug Information Journal. 2012:46(3);283–285.
7.
ZincRCMannG. On the importance of a single data standard. Drug Information Journal. 2012;46(3):362–367.
8.
MendoncaCMMcCaffreyDJBanahanBFBentleyJPYangY. Effect of direct-to-consumer drug advertising exposure on information search. Drug Information Journal. 2011:45(4);503–515.
9.
KaiserLBeckerCKukretiSFineB. Decision making for a companion diagnostic in an oncology clinical development program. Drug Information Journal. 2011:45(5);645–655.
10.
CoutantDRiggsDVan Sant HoffmanE. Substantial evidence: when is a single trial sufficient for approval and promotion?Drug Information Journal. 2011:45(3);253–263.
